Cytek Biosciences, Inc.
CTKB
$3.77
-$0.05-1.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.30% | 7.29% | -6.19% | 20.96% | 20.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.30% | 7.29% | -6.19% | 20.96% | 20.48% |
| Cost of Revenue | -5.40% | 8.03% | -1.63% | 36.12% | 32.82% |
| Gross Profit | 1.83% | 6.72% | -9.68% | 9.39% | 12.51% |
| SG&A Expenses | 5.50% | 4.21% | -4.74% | 3.12% | 14.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.19% | 2.44% | -6.25% | 12.88% | 20.97% |
| Operating Income | 381.75% | 33.83% | 6.57% | 11.74% | -263.10% |
| Income Before Tax | 151.11% | 103.75% | -8.96% | 0.52% | -0.07% |
| Income Tax Expenses | 148.85% | -134.52% | 247.17% | -26.47% | -451.52% |
| Earnings from Continuing Operations | 75.23% | 114.58% | -137.78% | 9.37% | 48.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.23% | 114.58% | -137.78% | 9.37% | 64.51% |
| EBIT | 381.75% | 33.83% | 6.57% | 11.74% | -263.10% |
| EBITDA | 49.93% | 48.48% | 10.15% | 19.05% | 76.80% |
| EPS Basic | 81.31% | 115.19% | -145.82% | 6.18% | 66.13% |
| Normalized Basic EPS | 94.79% | 103.65% | -12.87% | -2.88% | 17.79% |
| EPS Diluted | 73.48% | 114.40% | -147.68% | 0.40% | 65.73% |
| Normalized Diluted EPS | 94.79% | 103.65% | -12.87% | -2.88% | 32.41% |
| Average Basic Shares Outstanding | -3.34% | -3.80% | -3.29% | -3.37% | -1.09% |
| Average Diluted Shares Outstanding | -3.34% | -2.49% | -3.29% | -3.37% | -11.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |